Remove 2005 Remove Food and Drug Administration Remove Networking
article thumbnail

Pharma within planetary boundaries

European Pharmaceutical Review

In addition, the number of active substances detected in the environment has been increasing with unknown consequences for ecosystems and the accumulation of substances in food chains. Giving environmental risk assessments teeth Since 2005, the authorisation of a human pharmaceutical product requires an environmental risk assessment (ERA).

Pharma 98
article thumbnail

Direct to Patient Healthcare

Healthcare Success

When we launched Mayo Clinic’s social media network and podcast, I used what I like to call the ‘proceed until apprehended’ model of innovation. And so that's why we created what we then called the Mayo clinic social media network Lee Aase: as a way to kind of monetize our leadership in a sense, but also to do the things we wanted to do like.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ep. 001 – John Mack Podcast Transcript

Pharma Marketing Network

You know, in November 2009, the FDA held a public hearing about the promotion of Food and Drug Administrative Related Regulated Medical Products, using the internet and social media tools. They would write up the presentations by physicians about drugs. So that was 2005. So, I didn’t look so bad. It’s a blog.

Media 52
article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

Limitations of monoclonal antibody therapies Regulatory approvals from the US Food and Drug Administration (FDA) for aducanumab and lecanemab – and likely very soon for donanemab also – opened a route for different therapeutic modalities and other relevant disease targets, such as tau.

article thumbnail

Beyond instruments: streamlining process technology implementation in biopharmaceutical manufacturing

European Pharmaceutical Review

15 This includes network security and cybersecurity measures to protect sensitive data and prevent breaches, but also for data protection compliance with regional and applicable laws and regulations. International Council for Harmonisation (ICH), 2005. Q13 Continuous Manufacturing of Drug Substances and Drug Products.